MetaCap

Kura Oncology (KURA) vs Lexicon Pharmaceuticals (LXRX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Lexicon Pharmaceuticals (LXRX) has outperformed Kura Oncology (KURA) over the past year, gaining 14.2% versus a loss of 38.1%. Over five years, KURA leads with a -50.7% price change compared with -67.7% for LXRX. Lexicon Pharmaceuticals is the larger company by market cap ($681.2 million vs $634.9 million), about 1.1 times the size.

Lexicon Pharmaceuticals converts more of its revenue into profit, with a net margin of -101.1% versus -412.9%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

KURA-38.14%LXRX+14.18%
+104%+29%-46%
Nov 21, 20251 yearNov 20, 2026
KURA-59.33%LXRX-69.15%
+45%-27%-99%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

KURA versus LXRX key metrics
MetricKURALXRX
Share price$6.91$1.53
Market cap$634.88M$681.21M
1-day change-5.99%-8.38%
YTD return-33.49%+33.04%
1-year return-38.14%+14.18%
5-year return-50.66%-67.72%
EPS (TTM)$-3.30$-0.15
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$67.48M$49.80M
Revenue growth (YoY)+25.24%+60.24%
Net income (latest FY)$-278.67M$-50.34M
Gross margin—99.45%
Operating margin-449.94%-98.21%
Net margin-412.95%-101.08%
52-week high$13.90$2.68
52-week low$6.75$1.10
Distance from 52-week high-50.29%-42.91%
Analyst consensusstrong_buybuy
Avg. price target upside+357.60%+195.42%
Average volume2.10M2.56M
Shares outstanding91.88M445.23M
Employees26081
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • LXRX has outperformed KURA by 52.3 percentage points over the past year.
  • Lexicon Pharmaceuticals is more profitable, keeping -101.1 cents of every revenue dollar as net income versus -412.9 cents for Kura Oncology.
  • Lexicon Pharmaceuticals grew revenue faster in its latest fiscal year (+60.24% vs +25.24%).

About Kura Oncology

KURA stock →

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; Darlifarnib, a Phase 1 first-in-human FIT-001 trial which includes multiple cohorts to evaluate darlifarnib in combination with other targeted therapies in large solid tumor indications; and KO-7246, a next-generation menin inhibitor, for use in diabetes and cardiometabolic disorders and additional next-generation menin inhibitors for use in combination with other therapies in solid tumors.

Health Care · Biotechnology: Pharmaceutical Preparations · 260 employees

About Lexicon Pharmaceuticals

LXRX stock →

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. The company develops sotagliflozin, an orally-delivered small molecule drug for the treatment of hypertrophic cardiomyopathy, and ZYNQUISTA (sotagliflozin) for the treatment of type 1 diabetes.

Health Care · Biotechnology: Pharmaceutical Preparations · 81 employees

KURA vs LXRX FAQ

Which is bigger, Kura Oncology or Lexicon Pharmaceuticals?

Lexicon Pharmaceuticals (LXRX) is larger, with a market capitalization of $681.21M compared with $634.88M for Kura Oncology (KURA).

Which stock has performed better over the past year, KURA or LXRX?

LXRX returned +14.18% over the past 12 months, compared with -38.14% for KURA (price return, excluding dividends). Past performance does not predict future results.

Are Kura Oncology and Lexicon Pharmaceuticals in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons